for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eli Lilly And Co

LLY.N

Latest Trade

144.61USD

Change

-0.95(-0.65%)

Volume

446,440

Today's Range

144.38

 - 

147.09

52 Week Range

116.00

 - 

170.75

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
145.56
Open
145.56
Volume
446,440
3M AVG Volume
86.48
Today's High
147.09
Today's Low
144.38
52 Week High
170.75
52 Week Low
116.00
Shares Out (MIL)
956.58
Market Cap (MIL)
139,240.00
Forward P/E
20.09
Dividend (Yield %)
2.03

Next Event

Eli Lilly and Co 2021 Guidance Call

Latest Developments

More

Lilly's Neutralizing Antibody Bamlanivimab Receives Interim Authorization From Health Canada As A Treatment For Covid-19

Lilly And Precision Biosciences Announce Genome Editing Research Collaboration And License Agreement

Ypsomed Holding And Lilly Collaborate To Advance Automated Insulin Delivery System

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Eli Lilly And Co

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Industry

Biotechnology & Drugs

Contact Info

Lilly Corporate Ctr

Drop Code 1094, Lilly Corporate Ctr

INDIANAPOLIS, IN

46285-0001

United States

+1.317.2762000

https://www.lilly.com/

Executive Leadership

David A. Ricks

Chairman of the Board, President, Chief Executive Officer

Joshua L. Smiley

Chief Financial Officer, Senior Vice President

Aarti Shah

Senior Vice President - Chief Information and Digital Officer

Daniel M. Skovronsky

Senior Vice President, Chief Scientific Officer and President, Lilly Research Laboratories

Melissa Stapleton Barnes

Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer

Key Stats

2.35 mean rating - 20 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.9K

2018

24.6K

2019

22.3K

2020(E)

23.8K
EPS (USD)

2017

4.280

2018

5.550

2019

6.040

2020(E)

7.253
Price To Earnings (TTM)
23.83
Price To Sales (TTM)
6.00
Price To Book (MRQ)
28.84
Price To Cash Flow (TTM)
20.27
Total Debt To Equity (MRQ)
350.58
LT Debt To Equity (MRQ)
338.41
Return on Investment (TTM)
18.96
Return on Equity (TTM)
13.62

Latest News

Latest News

Eli Lilly to supply 26,000 doses of COVID-19 antibody drug to Canada

Eli Lilly and Co said on Tuesday it has signed an agreement with the Canadian government to supply 26,000 doses of its antibody drug to treat COVID-19 patients for $32.5 million.

Eli Lilly to supply 26,000 doses of COVID-19 antibody drug to Canada

Eli Lilly and Co said on Tuesday it has signed an agreement with the Canadian government to supply its antibody drug, bamlanivimab, to treat COVID-19 patients.

Canada grants interim authorization to Eli Lilly's COVID-19 antibody drug

Canada has granted interim authorization to Eli Lilly's antibody drug for treating COVID-19 in patients who are not hospitalized, but are at risk of serious illness because of their age or other conditions, the drugmaker said on Friday.

Canada grants interim authorization to Eli Lilly's COVID-19 antibody drug

Canada has granted interim authorization to Eli Lilly's antibody drug for treating COVID-19 in patients who are not hospitalized, but are at risk of serious illness because of their age or other conditions, the drugmaker said on Friday.

Eli Lilly arthritis drug gets FDA nod for emergency use with remdesivir to treat COVID-19

The U.S. Food and Drug Administration on Thursday approved the emergency use of Eli Lilly and Co's arthritis drug, baricitinib, in combination with Gilead Sciences Inc's remdesivir, to treat COVID-19 patients.

Eli Lilly drug gets FDA nod for emergency use with remdesivir to treat COVID-19

The U.S. Food and Drug Administration on Thursday approved emergency use of Eli Lilly and Co's antibody drug baricitinib, in combination with remdesivir, to treat COVID-19 patients.

Samsung BioLogics says mass producing Eli Lilly's COVID-19 treatment

Samsung BioLogics Co Ltd on Tuesday said it is mass-producing a COVID-19 antibody treatment developed by Eli Lilly and Co, as the United States began distributing the drug last week after emergency-use approval.

Samsung BioLogics says mass producing Eli Lilly's COVID-19 treatments

Samsung BioLogics said on Tuesday that it is mass producing COVID-19 antibody treatments developed by Eli Lilly and Co.

Shanghai Junshi delays drug trials, focuses on COVID-19 treatment

A shortage of lab monkeys and a focus on developing a COVID-19 treatment have prompted Shanghai Junshi Biosciences to push back clinical trials of some other drugs, an executive at U.S. drugmaker Eli Lilly's <LLY.N> Chinese partner said.

Fauci stresses on need for equitable access of COVID-19 vaccines

U.S. infectious disease expert Anthony Fauci said on Thursday vaccine developers should push to make billions of their COVID-19 vaccines to ensure access to all parts of the world, instead of focusing on the rich countries.

Fauci stresses on need for equitable access of COVID-19 vaccines

U.S. infectious disease expert Anthony Fauci said on Thursday vaccine developers should push to make billions of their COVID-19 vaccines to ensure access to all parts of the world, instead of focusing on the rich countries.

Health secretary says U.S. will ensure equitable distribution of coronavirus treatment

U.S. Health Secretary Alex Azar said on Tuesday the U.S. government would ensure equitable distribution of Eli Lilly's antibody treatment for COVID-19 patients, starting first with hospitals and areas where there are many cases.

U.S. allows emergency use of first COVID-19 antibody drug

U.S. regulators on Monday authorized emergency use of the first experimental antibody drug for COVID-19 in patients who are not hospitalized but are at risk of serious illness because of their age or other conditions.

U.S. allows emergency use of Eli Lilly's COVID-19 antibody therapy

The U.S. Food and Drug Administration on Monday authorized emergency use of Eli Lilly and Co's experimental COVID-19 antibody treatment, which President Donald Trump has praised and vowed to make available free of cost for all Americans.

U.S. strikes deal with Lilly for potential COVID-19 antibody drug

The U.S. government has agreed to pay $375 million to Eli Lilly and Co <LLY.N> for 300,000 doses of its experimental COVID-19 antibody treatment, a drug similar to a treatment that U.S. President Donald Trump received.

Eli Lilly signs deal with U.S. for 300,000 vials of potential COVID-19 drug

Eli Lilly and Co said on Wednesday it signed an agreement with the U.S. government to supply 300,000 vials of its experimental antibody drug to treat COVID-19 for $375 million. (Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb Chakrabarty)

US STOCKS-S&P 500, Dow slip on earnings worries, stimulus uncertainty

* Indexes: Dow down 0.28%, S&P down 0.03%, Nasdaq up 0.56% (Adds comment, details; updates prices)

US STOCKS-S&P 500 flat after Monday's selloff as focus turns to corporate earnings

* Indexes: Dow down 0.26%, S&P flat, Nasdaq up 0.47% (Updates to market open)

Lilly hires external adviser for COVID-19 drug plant problems

Eli Lilly and Co <LLY.N> said late on Tuesday it had hired an independent consultant to review a plant producing its COVID-19 antibody drug after receiving a notice from the U.S. health regulator.

Lilly hires outside advisor for COVID drug plant problems

Eli Lilly and Co said late on Tuesday it had hired an independent consultant to review a plant producing its promising COVID-19 drug after receiving notices from the U.S. health regulator.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up